Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00133523 · ClinicalTrials.gov registry record · Phase 4
FLU-VACS Comparative Study in Adults
A Phase 4 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 4
- Development phase
- 2,349
- Enrollment target
NCT00133523: Completed Phase 4 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00133523 is a Phase 4 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,349 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (353% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00133523, a Phase 4 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2,349 participants
- Enrollment target
Study Summary
The purpose of this study is to compare 2 licensed flu vaccines to each other and to placebo (inactive substance). The study will be conducted among healthy adult participants aged 18-49 years and is expected to last 3 years. During year 1, participants will be assigned to receive 1 of the 2 licensed flu vaccines or placebo, given as either nasal spray (live-attenuated vaccine or placebo) or injection (inactivated vaccine or placebo). Participants will receive the same assigned vaccine or placebo during year 2. During year 3, participants will be followed, but will not receive flu vaccine. Each year blood samples will be collected before and 1 month after each vaccination and at the end of each flu season in order to measure how the body responds to the vaccine and how well participants were protected from the flu. During the flu season, participants with flu-like illness will provide information on symptoms and provide a throat swab to test for virus identification.
Interventions
- OTHER Placebo
- BIOLOGICAL Trivalent inactivated influenza vaccine
- BIOLOGICAL Cold-adapted live attenuated influenza virus vaccine, trivalent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,349 participants |
| Start Date | 2004-10 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
What the finished NCT00133523 record still lists
NCT00133523 is an interventional study that assigns participants to a tested intervention. Its 2,349 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (353% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00133523 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00133523 about?
NCT00133523 is a clinical study titled "FLU-VACS Comparative Study in Adults". The purpose of this study is to compare 2 licensed flu vaccines to each other and to placebo (inactive substance). The study will be conducted among healthy adult participants aged 18-49 years and is expected to last 3 years. During year 1, participants will be assigned to receive 1 of the 2 license...
What is the current status of trial NCT00133523?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,349 participants. The study started on 2004-10. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00133523?
The interventions under investigation include: Placebo (OTHER), Trivalent inactivated influenza vaccine (BIOLOGICAL), Cold-adapted live attenuated influenza virus vaccine, trivalent (BIOLOGICAL).
Who is sponsoring clinical trial NCT00133523?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00133523's enrollment target sits among peer trials
2,349 31st of 2000 higher than 1,970 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00025935 · 2,350 participants
Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder
- NCT03099850 · 2,345 participants
Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies
- NCT06679140 · 2,330 participants · Phase 3
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
- NCT05868421 · 2,376 participants · NA
Veteran Social Support for Enhancing Use of Smoking Cessation Treatment
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia